JP7077226B2 - Ｃｄ４７及びｅｇｆｒの二重標的化による癌治療 - Google Patents

Ｃｄ４７及びｅｇｆｒの二重標的化による癌治療 Download PDF

Info

Publication number
JP7077226B2
JP7077226B2 JP2018530075A JP2018530075A JP7077226B2 JP 7077226 B2 JP7077226 B2 JP 7077226B2 JP 2018530075 A JP2018530075 A JP 2018530075A JP 2018530075 A JP2018530075 A JP 2018530075A JP 7077226 B2 JP7077226 B2 JP 7077226B2
Authority
JP
Japan
Prior art keywords
egfr
antibody
cancer
cells
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018530075A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019505485A (ja
JP2019505485A5 (https=
Inventor
エル． ワイズマン，アービング
マリー マッケンナ，ケリー
ウィリンガム，ステファン
ポイ ホー，ドリス
ディー． ダレルバ，ピエロ
フォルクマー，ジェンス－ピーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2019505485A publication Critical patent/JP2019505485A/ja
Publication of JP2019505485A5 publication Critical patent/JP2019505485A5/ja
Priority to JP2022081697A priority Critical patent/JP7494245B2/ja
Application granted granted Critical
Publication of JP7077226B2 publication Critical patent/JP7077226B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Zoology (AREA)
JP2018530075A 2015-12-11 2016-12-08 Ｃｄ４７及びｅｇｆｒの二重標的化による癌治療 Active JP7077226B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022081697A JP7494245B2 (ja) 2015-12-11 2022-05-18 Ｃｄ４７及びｅｇｆｒの二重標的化による癌治療

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562266470P 2015-12-11 2015-12-11
US62/266,470 2015-12-11
US201662380177P 2016-08-26 2016-08-26
US62/380,177 2016-08-26
PCT/US2016/065641 WO2017100462A2 (en) 2015-12-11 2016-12-08 Treatment of cancer with dual targeting of cd47 and egfr

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022081697A Division JP7494245B2 (ja) 2015-12-11 2022-05-18 Ｃｄ４７及びｅｇｆｒの二重標的化による癌治療

Publications (3)

Publication Number Publication Date
JP2019505485A JP2019505485A (ja) 2019-02-28
JP2019505485A5 JP2019505485A5 (https=) 2019-12-05
JP7077226B2 true JP7077226B2 (ja) 2022-05-30

Family

ID=59013321

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018530075A Active JP7077226B2 (ja) 2015-12-11 2016-12-08 Ｃｄ４７及びｅｇｆｒの二重標的化による癌治療
JP2022081697A Active JP7494245B2 (ja) 2015-12-11 2022-05-18 Ｃｄ４７及びｅｇｆｒの二重標的化による癌治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022081697A Active JP7494245B2 (ja) 2015-12-11 2022-05-18 Ｃｄ４７及びｅｇｆｒの二重標的化による癌治療

Country Status (8)

Country Link
US (3) US10344094B2 (https=)
EP (1) EP3386545A4 (https=)
JP (2) JP7077226B2 (https=)
KR (2) KR20250004896A (https=)
CN (2) CN115569192A (https=)
AU (3) AU2016365829B2 (https=)
CA (1) CA3005911A1 (https=)
WO (1) WO2017100462A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022116095A (ja) * 2015-12-11 2022-08-09 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Ｃｄ４７及びｅｇｆｒの二重標的化による癌治療

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10568383B2 (en) * 2015-01-16 2020-02-25 Nike, Inc. Sole system for an article of footwear incorporating a knitted component with a one-piece knit outsole and a tensile element
US9848673B2 (en) 2015-01-16 2017-12-26 Nike, Inc. Vacuum formed knit sole system for an article of footwear incorporating a knitted component
EP3341015B2 (en) * 2015-08-26 2023-12-27 The Board of Trustees of the Leland Stanford Junior University Enhanced depletion of targeted cells with cd47 blockade and an immune costimulatory agonist
EP3747906A1 (en) 2016-01-11 2020-12-09 Forty Seven, Inc. Humanized, mouse or chimeric anti-cd47 monoclonal antibodies
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
EP3529276A4 (en) 2016-10-21 2020-06-17 Arch Oncology, Inc. CD47 THERAPEUTIC ANTIBODIES
EP3532497B1 (en) 2016-10-26 2024-07-24 The Board of Trustees of the Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
SI4177270T1 (sl) * 2017-10-18 2024-10-30 Forty Seven, Inc. Terapija za raka jajčnikov na osnovi sredstva proti cd47
KR20200091901A (ko) 2017-12-01 2020-07-31 시애틀 지네틱스, 인크. 암을 치료하기 위한 cd47 항체 및 이의 용도
AU2019218271B2 (en) 2018-02-12 2024-12-12 Forty Seven, LLC Anti-cancer regimen using anti-CD47 and anti-CD20 antibodies
US20210040219A1 (en) * 2018-03-13 2021-02-11 Trillium Therapeutics Inc. Improvements in cd47 blockade therapy by egfr antibody
MX2020009774A (es) 2018-03-21 2020-10-08 Alx Oncology Inc Anticuerpos contra proteína alfa reguladora de señal y métodos de uso.
CN110331200A (zh) * 2019-06-28 2019-10-15 中山大学附属第六医院 Cd47检测试剂在制备结直肠癌对抗egfr单抗耐药诊断剂方面的应用
WO2021046216A1 (en) * 2019-09-03 2021-03-11 Arch Oncology, Inc. Methods for identifying biomarkers to predict treatment response
GB201918230D0 (en) 2019-12-11 2020-01-22 Prec Therapeutics Ltd Antibodies and their uses
WO2023165618A1 (en) * 2022-03-04 2023-09-07 Nanjing University Methods for treating cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013545452A (ja) 2010-10-29 2013-12-26 イミュノジェン， インコーポレイテッド 非拮抗性ｅｇｆｒ結合分子およびその免疫複合体

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
EP2111869A1 (en) * 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
PL2560658T3 (pl) * 2010-04-21 2017-08-31 Ventirx Pharmaceuticals, Inc. Wzmacnianie cytotoksyczności komórkowej zależnej od przeciwciał
HRP20221260T1 (hr) 2010-05-14 2023-03-03 The Board Of Trustees Of The Leland Stanford Junior University Humanizirana i kimerna monoklonska protutijela za cd47
US9233171B2 (en) * 2011-11-21 2016-01-12 Immunogen, Inc. Method of treatment of tumors that are resistant to EGFR antibody therapies by EGFR antibody cytotoxic agent conjugate
SI2804617T1 (sl) 2012-01-17 2020-10-30 The Board Of Trustees Of The Leland Stanford Junior University Visokoafinitetni SIRP-alfa reagenti
US20140134158A1 (en) * 2012-05-22 2014-05-15 Alberto Bardelli Kras mutations and resistance to anti-egfr treatment
CN105121467B (zh) * 2012-12-03 2019-07-05 诺夫免疫股份有限公司 抗cd47抗体及其使用方法
CN105101997B (zh) * 2013-02-06 2018-11-09 印希彼有限合伙公司 不减少血小板和不减少血红细胞的cd47抗体及其使用方法
AU2014227638A1 (en) * 2013-03-15 2015-09-17 Merck Patent Gmbh Tetravalent bispecific antibodies
PT2970493T (pt) 2013-03-15 2019-06-27 Univ Leland Stanford Junior Métodos para obter doses terapeuticamente eficazes de agentes anti-cd47
ES2898627T3 (es) 2013-04-29 2022-03-08 Univ Leland Stanford Junior Uso de agentes anti-CD47 para mejorar la inmunización
ES3012974T3 (en) * 2014-01-08 2025-04-10 Univ Leland Stanford Junior Targeted therapy for lung cancer
AU2015229448B2 (en) * 2014-03-11 2020-09-03 The Board Of Trustees Of The Leland Stanford Junior University Anti SIRP-alpha antibodies and Bi-specific Macrophage Enhancing antibodies
EP3209769B1 (en) * 2014-10-24 2020-08-05 The Board of Trustees of the Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
US20160036232A1 (en) 2015-10-09 2016-02-04 LT Lighting (Taiwan) Corp. Maximum energy utilization point tracking technologies
AU2016365829B2 (en) * 2015-12-11 2020-02-06 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cancer with dual targeting of CD47 and EGFR
CN107459579B (zh) * 2016-06-01 2021-09-24 泰州迈博太科药业有限公司 一种靶向egfr和cd47双特异性融合蛋白、制备方法及应用
CN106519036B (zh) * 2016-11-04 2019-06-11 新乡医学院 抗cd47和egfr的双功能蛋白及其制备方法与应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013545452A (ja) 2010-10-29 2013-12-26 イミュノジェン， インコーポレイテッド 非拮抗性ｅｇｆｒ結合分子およびその免疫複合体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Biochem. Biophys. Res. Commun., (2013), 441, [4], p.707-712
PLoS One, (2015.9), Article.e0137345(p.1-23), doi:10.1371/journal.pone.0137345
Radiother. Oncol., (2015.9), 116, [3], p.510-516

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022116095A (ja) * 2015-12-11 2022-08-09 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Ｃｄ４７及びｅｇｆｒの二重標的化による癌治療
JP7494245B2 (ja) 2015-12-11 2024-06-03 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Ｃｄ４７及びｅｇｆｒの二重標的化による癌治療

Also Published As

Publication number Publication date
JP2019505485A (ja) 2019-02-28
US20170166645A1 (en) 2017-06-15
KR20250004896A (ko) 2025-01-08
WO2017100462A2 (en) 2017-06-15
US11130813B2 (en) 2021-09-28
US10344094B2 (en) 2019-07-09
AU2020202712B2 (en) 2023-01-05
EP3386545A2 (en) 2018-10-17
AU2016365829A1 (en) 2018-06-07
AU2023201938B2 (en) 2025-11-20
CA3005911A1 (en) 2017-06-15
US20190322751A1 (en) 2019-10-24
US20220033506A1 (en) 2022-02-03
AU2020202712A1 (en) 2020-05-14
CN115569192A (zh) 2023-01-06
AU2023201938A1 (en) 2023-05-04
US12037402B2 (en) 2024-07-16
JP2022116095A (ja) 2022-08-09
KR102763202B1 (ko) 2025-02-07
AU2016365829B2 (en) 2020-02-06
EP3386545A4 (en) 2019-06-05
JP7494245B2 (ja) 2024-06-03
KR20180083895A (ko) 2018-07-23
CN108367073A (zh) 2018-08-03

Similar Documents

Publication Publication Date Title
JP7494245B2 (ja) Ｃｄ４７及びｅｇｆｒの二重標的化による癌治療
JP7343528B2 (ja) 抗ｃｄ４７抗体及び抗ｃｄ２０抗体を使用する抗がんレジメン
JP6840127B2 (ja) がんの治療における抗ｐｄ−１抗体および抗ｍ−ｃｓｆ抗体の併用
JP7026047B2 (ja) 免疫調節剤を併用するがんの治療
JP2020522691A (ja) Ｌａｇ−３陽性腫瘍の処置
JP2021138756A (ja) 腫瘍細胞の枯渇を亢進するための薬剤の組み合わせ
KR20220091576A (ko) 혈액암의 항-cd47 및 항-cd20 기반 치료
JP2024116225A (ja) 黒色腫に対する併用療法
JP2021500349A (ja) 抗ｃｄ４７剤ベースの卵巣癌療法
JP7308190B2 (ja) 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置
JP2022511337A (ja) 免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物
JP2022532519A (ja) 限られた数のｎｋ細胞を有する患者における抗ｃｄ１９療法
WO2025145207A1 (en) Combination therapy of kras inhibitor and treg-depleting agent
TW202321309A (zh) 使用至少結合ｅｇｆｒ之抗體治療免疫檢查點抑制劑治療之具高ｅｇｆｒ表現的癌症
HK40084229A (en) Treatment of cancer with dual targeting of cd47 and egfr
HK1259512A1 (en) Treatment of cancer with dual targeting of cd47 and egfr
EA045764B1 (ru) Иммунотерапия злокачественных опухолей путем нарушения передачи сигналов pd-1/pd-l1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220124

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220419

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220518

R150 Certificate of patent or registration of utility model

Ref document number: 7077226

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250